NLTX
Neoleukin Therapeutics, Inc. [NLTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NLTX Stock Summary
In the News
NLTX Financial details
Company Rating
Neutral
Market Cap
8.2M
Income
-39.36M
Revenue
0
Book val./share
6.78
Cash/share
7.07
Dividend
-
Dividend %
-
Employees
7
Optionable
No
Shortable
Yes
Earnings
18 Mar 2024
P/E
-0.98
Forward P/E
-
PEG
-0.07
P/S
-
P/B
0.51
P/C
0.49
P/FCF
-0.25
Quick Ratio
15.06
Current Ratio
15.33
Debt / Equity
0.14
LT Debt / Equity
0.12
-
-
EPS (TTM)
-2.64
EPS next Y
-
EPS next Q
-
EPS this Y
-4.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.5%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
115.79%
-
-
-
-
SMA20
-35.71%
SMA50
-
SMA100
-
Inst Own
31.4%
Inst Trans
1.16%
ROA
-44%
ROE
-48%
ROC
-0.45%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.42-18.8
52W High
-80.61%
52W Low
+16.33%
RSI
17
Rel Volume
19.76
Avg Volume
5.52K
Volume
109.1K
Perf Week
-73.56%
Perf Month
-74.26%
Perf Quarter
-
Perf Half Y
-75.49%
-
-
-
-
Beta
1.102
-
-
Volatility
4.98%, 3.5%
Prev Close
0%
Price
3.49
Change
0%
NLTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.06 | 0 | 0.01 | 0 | 0 | |
| Net income per share | -1.34 | -2.57 | -0.48 | -1.06 | -1.01 | |
| Operating cash flow per share | -1.34 | -0.57 | -0.47 | -0.86 | -0.83 | |
| Free cash flow per share | -1.34 | -0.6 | -0.52 | -0.92 | -0.85 | |
| Cash per share | 3.27 | 5.29 | 3.72 | 2.59 | 1.75 | |
| Book value per share | 3.09 | 5.24 | 3.69 | 2.6 | 1.71 | |
| Tangible book value per share | 3.09 | 5.22 | 3.68 | 2.59 | 1.71 | |
| Share holders equity per share | 3.09 | 5.24 | 3.69 | 2.6 | 1.71 | |
| Interest debt per share | 0 | 0.04 | 0.23 | 0.24 | 0.25 | |
| Market cap | 1.02B | 6.66B | 14.61B | 5.31B | 562.15M | |
| Enterprise value | 939.12M | 6.52B | 14.43B | 5.18B | 536.33M | |
| P/E ratio | -32.17 | -95.92 | -585.62 | -90.83 | -10.04 | |
| Price to sales ratio | 40.64 | 0 | 32.41K | 884.34K | 0 | |
| POCF ratio | -32.18 | -432.65 | -594.7 | -111.57 | -12.33 | |
| PFCF ratio | -32.13 | -409.28 | -545.45 | -104.41 | -12.03 | |
| P/B Ratio | 13.98 | 47.01 | 76.43 | 37.14 | 5.96 | |
| PTB ratio | 13.98 | 47.01 | 76.43 | 37.14 | 5.96 | |
| EV to sales | 37.56 | 0 | 32K | 862.76K | 0 | |
| Enterprise value over EBITDA | -29.81 | -305.04 | -303.47 | -85.28 | -9.5 | |
| EV to operating cash flow | -29.74 | -423.44 | -587.35 | -108.85 | -11.76 | |
| EV to free cash flow | -29.69 | -400.57 | -538.71 | -101.86 | -11.48 | |
| Earnings yield | -0.03 | -0.01 | 0 | -0.01 | -0.1 | |
| Free cash flow yield | -0.03 | 0 | 0 | -0.01 | -0.08 | |
| Debt to equity | 0 | 0.01 | 0.06 | 0.09 | 0.13 | |
| Debt to assets | 0 | 0.01 | 0.06 | 0.08 | 0.1 | |
| Net debt to EBITDA | 2.44 | 6.64 | 3.79 | 2.13 | 0.46 | |
| Current ratio | 16.68 | 30.28 | 24.66 | 16.67 | 8.96 | |
| Interest coverage | -8.16K | -70.96K | 0 | 0 | -37.36 | |
| Income quality | 1 | 0.22 | 0.74 | 0.78 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.01 | -0.01 | 0 | 0 | |
| Sales general and administrative to revenue | 0.63 | 0 | 38.16 | 3.59K | 0 | |
| Research and developement to revenue | 1.67 | 0 | 53.98 | 6.53K | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.06 | 0.09 | 0.07 | 0.02 | |
| Capex to revenue | 0 | 0 | -4.92 | -543.83 | 0 | |
| Capex to depreciation | 0 | -2.59 | -1.22 | -1.43 | -0.42 | |
| Stock based compensation to revenue | 0.19 | 0 | 12.47 | 1.93K | 0 | |
| Graham number | 9.66 | 17.41 | 6.32 | 7.87 | 6.24 | |
| ROIC | -0.43 | -0.49 | -0.12 | -0.35 | -0.49 | |
| Return on tangible assets | -0.41 | -0.47 | -0.12 | -0.36 | -0.48 | |
| Graham Net | 3.07 | 5.11 | 3.34 | 2.22 | 1.35 | |
| Working capital | 72.54M | 138.85M | 186.63M | 135.35M | 88.07M | |
| Tangible asset value | 72.67M | 141.12M | 190.87M | 142.74M | 94.33M | |
| Net current asset value | 72.22M | 138.26M | 175.22M | 123.59M | 77.52M | |
| Invested capital | 0 | 0.01 | 0.06 | 0.09 | 0.13 | |
| Average receivables | 488.5K | 370K | 251.5K | 0 | 0 | |
| Average payables | 3.36M | 1.15M | 1.46M | 924.5K | 502K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 3.46 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 105.49 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.43 | -0.49 | -0.13 | -0.41 | -0.59 | |
| Capex per share | 0 | -0.03 | -0.04 | -0.06 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.13 | -0.23 | -1.81 | -0.19 | -0.41 | |
| Operating cash flow per share | -0.84 | -0.2 | -1.18 | -0.36 | -0.38 | |
| Free cash flow per share | -0.87 | -0.2 | -1.21 | -0.37 | -0.38 | |
| Cash per share | 9.67 | 1.74 | 7.53 | 7.31 | 7.07 | |
| Book value per share | 9.56 | 1.71 | 7.34 | 7.08 | 6.78 | |
| Tangible book value per share | 9.56 | 1.71 | 7.34 | 7.08 | 6.78 | |
| Share holders equity per share | 9.56 | 1.71 | 7.34 | 7.08 | 6.78 | |
| Interest debt per share | 1.14 | 0.23 | 0.97 | 0.98 | 0.96 | |
| Market cap | 141.44M | 562.8M | 155.18M | 186.45M | 175.4M | |
| Enterprise value | 113.18M | 536.99M | 131.37M | 166.38M | 160.87M | |
| P/E ratio | -2.82 | -11.13 | -1.93 | -22.36 | -9.69 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.23 | -51.48 | -11.91 | -46.05 | -41.09 | |
| PFCF ratio | -14.72 | -50.99 | -11.54 | -44.59 | -41.09 | |
| P/B Ratio | 1.34 | 5.97 | 1.91 | 2.34 | 2.33 | |
| PTB ratio | 1.34 | 5.97 | 1.91 | 2.34 | 2.33 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -8.69 | -39.46 | -17.1 | -61.74 | -31.01 | |
| EV to operating cash flow | -12.18 | -49.12 | -10.08 | -41.09 | -37.68 | |
| EV to free cash flow | -11.78 | -48.65 | -9.77 | -39.79 | -37.68 | |
| Earnings yield | -0.09 | -0.02 | -0.13 | -0.01 | -0.03 | |
| Free cash flow yield | -0.07 | -0.02 | -0.09 | -0.02 | -0.02 | |
| Debt to equity | 0.11 | 0.13 | 0.14 | 0.14 | 0.14 | |
| Debt to assets | 0.1 | 0.1 | 0.12 | 0.12 | 0.12 | |
| Net debt to EBITDA | 2.17 | 1.9 | 3.1 | 7.45 | 2.8 | |
| Current ratio | 10.63 | 8.96 | 11.97 | 17.17 | 15.33 | |
| Interest coverage | -24.35 | -17.46 | 16.26 | 0 | 0 | |
| Income quality | 0.71 | 0.81 | 0.92 | 1.94 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.03 | 0.03 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.55 | -0.16 | -0.68 | -0.36 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.62 | 2.96 | 17.31 | 5.44 | 7.88 | |
| ROIC | -0.1 | -0.11 | -0.2 | -0.03 | -0.06 | |
| Return on tangible assets | -0.1 | -0.11 | -0.2 | -0.02 | -0.05 | |
| Graham Net | 7.78 | 1.35 | 5.98 | 6.02 | 5.78 | |
| Working capital | 98.62M | 88.07M | 78.48M | 78.9M | 74.68M | |
| Tangible asset value | 105.65M | 94.33M | 81.36M | 79.58M | 75.24M | |
| Net current asset value | 87.93M | 77.52M | 68.53M | 69.35M | 65.54M | |
| Invested capital | 0.11 | 0.13 | 0.14 | 0.14 | 0.14 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 8.37M | 4.67M | 239K | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.12 | -0.13 | -0.25 | -0.03 | -0.06 | |
| Capex per share | -0.03 | 0 | -0.04 | -0.01 | 0 |
NLTX Frequently Asked Questions
What is Neoleukin Therapeutics, Inc. stock symbol ?
Neoleukin Therapeutics, Inc. is a US stock , located in Seattle of Wa and trading under the symbol NLTX
What is Neoleukin Therapeutics, Inc. stock quote today ?
Neoleukin Therapeutics, Inc. stock price is $3.49 today.
Is Neoleukin Therapeutics, Inc. stock public?
Yes, Neoleukin Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 5.52K
- Market Capitalization 8.2M
- Employee 7
- CEO Ms. Donna M. Cochener-Metcalfe J.D.
- Headquarters Seattle,WA,US
- IPO Date 2014-03-07
-
Website
https://www.neoleukin.com 
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
